A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Phase 1 Completed 39 enrolled X4 Pharmaceuticals

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to measure the effect of HI on the PK, safety, and tolerability of a single dose of mavorixafor compared to matched healthy volunteers (HVs) with normal hepatic function.

Timeline

Start: 2025-02-28
Primary completion: 2026-01-12
Completion: 2026-01-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mavorixafor	Small molecule	—	Oral

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Summary

Timeline

Drugs

Indications